AbbVie’s blockbuster cancer drug Imbruvica may hold onto its monopoly for at least another decade, thanks to a court ruling Thursday that found a generic drugmaker’s Imbruvica knockoff infringed on AbbVie’s patents.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,